TUSTIN, Calif., Nov. 20 /PRNewswire-FirstCall/ -- AMDL, Inc. , with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products, announced today that it has launched significant new expansion plans to increase annualized sales in FY2008, through the introduction of multiple new products and distribution strategies.
In concert with the expansion of JPI’s new Goodnak product, JPI expects to significantly expand its new JPGreen Health & Beauty Centers that are anticipated to provide a wide variety of anti-aging, beauty, cosmetic and spa related treatments and products for both women and men. There are currently five existing Jade Healthy Supermarkets store locations, which were previously announced, that are in the process of being converted into the new JPGreen retail store design.
Any future acquired stores will also be re-decorated in JPGreen style, and will highlight JPGreen and JPI products. These JPGreen locations, typically 300-900 square feet in size, are being developed through in-house store openings and through the acquisition of existing beauty and spa businesses. The typical JPGreen store location is anticipated to generate, on average, approximately $170,000 in annual sales with an average net profit margin of at least 30 percent. JPI has initially signed over 50 letters of intent with various existing beauty and spa businesses that have indicated their interest in being acquired and converted to JPGreen stores. JPI currently anticipates acquiring and converting up to 200 locations during late FY2007 and FY2008.
Frank Zheng, managing director of JPI, said this new expansion of the JPGreen store model has been well thought out and the company has the management talent pool and operational resources to meet this challenging expansion goal. Gary Dreher, CEO of AMDL said, “We expect to be in a position to provide the capital resources JPI will need in the coming months to allow them to execute their plans in a timely manner. We look forward to highly profitable China based operations in FY2008. We’ll continue to update the market as JPI achieves various milestones related to this expansion strategy.”
About JPI: Jade Pharmaceutical through its subsidiaries JJB & YYB has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
CONTACT: AMDL Investor Relations, Paul Knopick, +1-949-707-5365,
VoiceMail, +1-714-505-4460
Web site: http://www.amdl.com/
